(Reuters) – The U.S. government released its revised guidance for its Medicare drug price negotiation program on Friday, saying it clarified how it will identify treatments and allow drug companies to publicly discuss negotiation at their discretion.
In September, the US Centers for Medicare & Medicaid Spending will select 10 of the most expensive prescription drugs in the Medicare program and negotiate price cuts that will take effect in 2026.
Two major drugmakers and the industry’s top lobby group have filed lawsuits against the US government over the program, claiming it is unconstitutional.
(Reporting by Michael Erman)